Salmonella typhi vaccine strain cvd 908 expressing the circumsporozoite protein of plasmodium falciparum: Strain construction and safety and immunogenicity in humans

Journal of Infectious Diseases

Volumn 169, Issue 4, 1994, Pages 927-931

  Gonzalez, Cesar ^a,b,c,d   Hone, David ^a,b,c,d   Noriega, Fernando R ^a,b,c,d   Tacket, Carol O ^a,b,c,d   Davis, Jonathan R ^a,b,c,d   Losonsky, Genevieve ^a,b,c,d   Nataro, James P ^a,b,c,d   Hoffman, Stephen ^a,b,c,d   Malik, Anita ^a,b,c,d   Nardin, Elizabeth ^a,b,c,d   Sztein, Marcelo B ^a,b,c,d   Heppner, D Gray ^a,b,c,d   Fouts, Timothy R ^a,b,c,d   Isibasi, Armando ^a,b,c,d   Levine, Myron M ^a,b,c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Naval Medical Research Institute   (United States)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; O ANTIGEN; RECOMBINANT PROTEIN; SPOROZOITE VACCINE; TYPHOID VACCINE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALMONELLA TYPHI; SEROLOGY; VACCINATION;

ADMINISTRATION, ORAL; ADULT; AMINO ACID SEQUENCE; ANIMAL; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMAN; MALARIA VACCINES; MICE; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SALMONELLA TYPHI; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; VACCINES, SYNTHETIC;

EID: 0028273328     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.4.927     Document Type: Article

References (15)

1. Herrington DA. Davis JR. Nardin E, et al. Successful immunization of humans with irradiated malaria sporozoites: Humoral and cellular responses of the protected individuals. Am J Trap Med Hyg 1991;45:539-47.
2. Egan JE, Hoffman SL, Haynes JD, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993;49:166-73.
3. Nardin EH, Nussenzweig RS, Altszuler R. et al. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull World Health Organ 1990;68(suppl):85-7.
4. Malik A, Egan J, Houghten RA, Sadoflf JC. Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodiumfalciparum circumsporo-zoite protein. Proc Natl Acad Sei USA 1991;88:3300-4.
5. Davis JR. Cortese JF, Herrington DA, et al. Plasmodium falciparum: In vitro characterization and human infectivity of a cloned line. Exp Parasitol 1992;74:159-68.
6. Ballou WR. Hoffman SL. Sherwood J. et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987;2:1277-81.
7. Herrington DA, Clyde DF, Losonsky G. etal. Safety and immunogenic-ity in man of a synthetic peptide malaria vaccine against Plasmodium falciparumsporozoites. Nature 1987;328:257-9.
8. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc Natl Acad Sei USA 1992;89:358-62.
9. Sadofif JC, Ballou WR, Baron LS, et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988;240:336-8.
10. Hone DM. Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically defined double aro mutants of Salmonella lyplii. Vaccine 1991;9:810-6.
11. Tacket CO. Hone DH, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity ofCVD 908 Salmonella lyphi vaccine strain. Vaccine 1992;10:443-6.
12. Fouts TR, Lewis GK, Hone DM. Construction and characterization of a Salmonella-based HI V-1 vector vaccine. In: Ginsberg HS, Brown F. Chanock RM, Lerner RA. eds. Vaccines '93. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1993:95-9.
13. Calle JMC. Nardin EH. Clavijo P. et al. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite immunized volunteers. J Immunol 1992;149:2695-701.
14. Brown AE, Webster HK, Gordon DM, Permpanich B, Gross M. Characterization of naturally acquired antibodies to the non-repetitive flanking regions of the circumsporozoite protein of Plasmodium falciparum.Am J Trop Med Hyg 1992;47:440-5.
15. Del Guidice G. Cheng Q. Mazier D, et al. Immunogenicity of a non-re-petitive sequence of Plasmodium falciparum circumsporozoite protein in man and mice. Immunology 1988;63:187-91.